Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EUTHROID-3 vs EUTHROID-2
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.
EUTHROID-2 is a synthetic formulation of liothyronine (T3) and levothyroxine (T4) that replaces endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription to increase metabolic rate, oxygen consumption, and protein, carbohydrate, and lipid metabolism.
Hypothyroidism (thyroid hormone replacement therapy),Thyroid-stimulating hormone suppression in thyroid cancer (off-label)
Hypothyroidism: replacement therapy in primary (thyroidal), secondary (pituitary), or tertiary (hypothalamic) hypothyroidism,Suppression of thyrotropin (TSH) in euthyroid patients with nontoxic goiter or thyroid cancer (adjunctive therapy)
Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.
Oral, 1 tablet once daily. Each tablet contains levothyroxine 112 mcg and liothyronine 28.8 mcg.
L-T4: 6-7 days; L-T3: 1-2 days. Clinical context: Steady-state achieved in ~6 weeks for T4, ~8 days for T3.
T4: 6-7 days (euthyroid); T3: approximately 1 day; clinical context: requires 6-8 weeks for steady state with T4 therapy.
Levothyroxine (T4) is metabolized to liothyronine (T3) via deiodination in peripheral tissues (liver, kidney, etc.). Liothyronine (T3) is metabolized via deiodination and conjugation (glucuronidation and sulfation) in the liver and kidneys. Hepatic enzymes involved include deiodinases (D1, D2) and UDP-glucuronosyltransferases (UGTs).
Levothyroxine (T4) is metabolized via deiodination by type 1 and type 2 deiodinases in peripheral tissues to the active form liothyronine (T3) and to reverse T3 (r T3). Further metabolism involves conjugation (glucuronidation and sulfation) in the liver and excretion in bile and urine.
Renal (approx. 20-40% as unchanged drug and metabolites), biliary/fecal (approx. 60-80% as conjugated metabolites).
Renal: ~20-40% of T4 and T3 metabolites; fecal: ~40-60% as conjugated metabolites; minor biliary elimination.
99.8% for L-T4 (thyroxine-binding globulin, transthyretin, albumin); 99.7% for L-T3 (same proteins, lower affinity).
T4: >99.95% bound to TBG, TTR, albumin; T3: ~99.7% bound to same proteins; free fraction T4 ~0.03%, T3 ~0.3%.
L-T4: 0.1-0.2 L/kg (mainly intravascular); L-T3: 0.4-0.6 L/kg (broader tissue distribution).
T4: 0.1-0.2 L/kg (small); T3: 0.4-0.6 L/kg (larger due to less protein binding); clinical: reflects extensive tissue distribution for T3.
Oral L-T4: 80-90% (fasting; reduced by food and malabsorption). Oral L-T3: 95-100% (well absorbed).
Oral: T4 70-80% (fasting, consistent); T3 90-95%; IV: 100%.
No specific GFR-based dose adjustment required; monitor thyroid function in severe chronic kidney disease (GFR <30 m L/min/1.73 m²) as drug clearance may be reduced.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (GFR < 15 m L/min), monitor thyroid function closely and consider dose reduction by 25%.
No specific adjustment for Child-Pugh class A or B; use with caution in Child-Pugh C due to reduced hepatic conversion, monitor TSH.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 25%. Child-Pugh C: Reduce dose by 50% or avoid use.
Not FDA-approved for children; adult dose not suitable. For hypothyroidism in children, use levothyroxine monotherapy at 25-50 mcg/day for ages 1-3 years, 50-100 mcg/day for ages 3-10 years, and 100-150 mcg/day for ages 10-16 years, adjusted per TSH.
Weight-based dosing (levothyroxine equivalent): 1-2 mcg/kg/day orally. For neonates (0-3 months): 10-15 mcg/kg/day. Adjust based on TSH and free T4 levels.
Start with lower dose: 25 mcg levothyroxine/7.5 mcg liothyronine (half tablet) orally once daily, titrate slowly every 4-6 weeks based on TSH, due to increased risk of cardiac adverse effects and altered metabolism.
Start with lower dose (levothyroxine equivalent 25-50 mcg/day) and titrate slowly. Monitor for cardiac effects due to increased sensitivity.
None
No FDA boxed warning. However, inappropriate use (e.g., for obesity or weight loss) in euthyroid patients is dangerous and can cause serious or life-threatening toxicity, especially when combined with sympathomimetic amines.
Cardiac toxicity (e.g., arrhythmias, angina, myocardial infarction) due to excessive thyroid hormone levels,Thyrotoxic crisis (thyroid storm) if overdosed,Adrenal insufficiency: may precipitate acute adrenal crisis in patients with adrenal insufficiency,Delayed bone maturation in children if overtreated,Interactions with anticoagulants (increased INR), oral antidiabetic agents (hyperglycemia), and catecholamines (sympathomimetic effects)
Cardiac toxicity: Risk of tachyarrhythmias, angina, myocardial ischemia in patients with cardiovascular disease; start with low doses and titrate slowly,Thyrotoxic crisis: Accidental overdose may cause thyrotoxicosis or thyroid storm; monitor for symptoms of hyperthyroidism (tachycardia, chest pain, nervousness, insomnia),Adrenal insufficiency: Thyroid hormone therapy may increase cortisol clearance and precipitate acute adrenal crisis in patients with adrenal insufficiency; treat adrenal insufficiency prior to thyroid replacement,Osteoporosis: Long-term excessive thyroid hormone may cause decreased bone mineral density,Diabetes: May alter glucose metabolism; monitor blood glucose in diabetic patients,Warfarin interaction: Thyroid hormone potentiates anticoagulant effect of warfarin; reduce warfarin dose upon initiation of thyroid therapy
Untreated adrenal insufficiency,Thyrotoxicosis (any etiology),Acute myocardial infarction (recent),Hypersensitivity to any component
Hypersensitivity to any component of the product,Untreated or inadequately treated adrenal insufficiency,Untreated thyrotoxicosis (hyperthyroidism),Recent myocardial infarction (relative contraindication due to risk of cardiac ischemia),Concurrent use of sympathomimetic amines (e.g., for weight loss) may increase cardiac risk
Take on an empty stomach with water. Avoid concurrent intake with high-fiber foods, walnuts, soybean flour, cottonseed meal, or calcium/iron supplements within 4 hours of dosing as they may reduce absorption.
Avoid high-fiber foods, soy products, walnuts, grapefruit juice, and high-calcium foods (milk, yogurt) at the time of dosing as they can impair absorption. Take medication at least 30 minutes before meals. Foods containing goitrogens (e.g., cruciferous vegetables like broccoli, cabbage, kale) in large amounts may interfere with thyroid function but are generally not a concern with adequate iodine intake.
Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic risk from exogenous thyroid hormone. Fetal thyroid function develops at 10-12 weeks; prior to that, fetus depends on maternal T4. Overdose may cause fetal thyrotoxicosis. First trimester: maternal hypothyroidism increases risk of miscarriage and neurodevelopmental deficits. Second/third trimester: overtreatment may cause fetal tachycardia and growth restriction. Postpartum: adjust dose to prevent maternal hypothyroidism.
EUTHROID-2 (levothyroxine 100 mcg + liothyronine 20 mcg) is a combination thyroid hormone replacement. Hypothyroidism itself increases risk of miscarriage and fetal neurodevelopmental deficits if untreated. Levothyroxine and liothyronine do not cross the placenta in significant amounts at physiological doses and are not associated with congenital malformations. No teratogenic effects in first trimester. In second and third trimesters, maternal euthyroidism is critical; undertreatment may lead to fetal goiter, impaired neurological development, or preterm birth. Overtreatment carries risk of maternal tachycardia, arrhythmia, and potential fetal thyrotoxicosis. The benefit of treating maternal hypothyroidism outweighs risks.
Excreted in human milk in low amounts. T3 and T4 are endogenous hormones; exogenous administration results in minimal transfer. M/P ratio: not established for Euthroid-3, but for levothyroxine, M/P ratio ~0.001. Considered compatible with breastfeeding when used at recommended doses. Monitor infant for thyroid suppression (rare at maternal therapeutic doses).
Minimal excretion into breast milk. Both levothyroxine and liothyronine are endogenous hormones; exogenous doses result in negligible transfer. Milk-to-plasma ratio (M/P) < 0.01 for levothyroxine; liothyronine M/P ~0.3. Not expected to cause adverse effects in breastfed infants at usual maternal doses. No contraindication to breastfeeding with appropriate thyroid monitoring.
Pregnancy increases T4 clearance due to increased TBG and placental deiodination. Dose may need to increase by 20-50% as early as 4-6 weeks gestation. Start with increased dose of 30-50% of prepregnancy dose. Adjust based on TSH every 4-6 weeks. Typical dose increase: 30-50% above baseline. Liothyronine component may require adjustment; monitor free T3 if using T3 therapy. Postpartum: reduce dose back to prepregnancy level.
Pregnancy increases thyroid hormone requirements: increased thyroxine-binding globulin, increased plasma volume, and enhanced placental deiodinase activity. Typical dose increase of 25-50% from prepregnancy dose; some may require up to 50% more. Start increase as soon as pregnancy confirmed, guided by TSH. Split doses may be considered for liothyronine component due to short half-life. Postpartum, reduce to prepregnancy dose within 4-6 weeks.
Euthroid-3 is a combination of liothyronine (T3) and levothyroxine (T4) in a fixed 1:4 ratio. Monitor TSH, free T4, and free T3 levels to avoid iatrogenic hyperthyroidism. Adjust dose cautiously in elderly or cardiac patients. Use with caution in adrenal insufficiency as thyroid replacement can precipitate adrenal crisis.
Euthroid-2 is a synthetic combination of levothyroxine (T4) and liothyronine (T3) used for thyroid hormone replacement. Monitor TSH levels 6-8 weeks after dose changes; target TSH within normal range. T3 component may cause more rapid symptom relief but also risk of iatrogenic thyrotoxicosis if overdosed. Use with caution in elderly, cardiac disease, or adrenal insufficiency. Avoid abrupt discontinuation. Starting dose typically 50-100 mcg T4 equivalent; adjust per TSH. T3 half-life ~1 day vs T4 ~7 days; twice-daily dosing may be considered for T3 but Euthroid-2 is usually dosed once daily. Drug interactions: warfarin (increased INR), antidiabetic agents (need dose adjustment), beta-blockers (reduce T4 to T3 conversion).
Take exactly as prescribed, typically once daily on an empty stomach 30-60 minutes before breakfast.,Do not switch between different thyroid hormone products without consulting your doctor.,Report symptoms of hyperthyroidism (rapid heartbeat, chest pain, heat intolerance, excessive sweating) or hypothyroidism (fatigue, weight gain, cold intolerance).,Inform all healthcare providers you are taking this medication.,Store at room temperature away from light and moisture.
Take Euthroid-2 on an empty stomach, at least 30 minutes before breakfast or 2 hours after a meal, with a full glass of water.,Do not discontinue medication abruptly; consult your doctor before stopping.,Report symptoms of hyperthyroidism (rapid heartbeat, anxiety, tremors, weight loss, heat intolerance) or hypothyroidism (fatigue, weight gain, cold intolerance, depression).,Avoid iron supplements, calcium supplements, antacids, and sucralfate within 4 hours of taking Euthroid-2.,Consistent timing and brand are important; do not switch to generic or different brand without doctor approval.,Pregnancy: inform your doctor if pregnant or planning; dose may need adjustment.,Regular blood tests (TSH) are required to monitor therapy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EUTHROID-3 vs EUTHROID-2, answered by our medical review team.
EUTHROID-3 is a Thyroid Hormone Replacement that works by EUTHROID-3 is a combination of liothyronine (T3) and levothyroxine (T4) that supplements endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription and increasing metabolism, protein synthesis, and oxygen consumption.. EUTHROID-2 is a Thyroid Hormone Replacement that works by EUTHROID-2 is a synthetic formulation of liothyronine (T3) and levothyroxine (T4) that replaces endogenous thyroid hormone. T4 is converted to the active T3 in peripheral tissues. T3 binds to thyroid hormone receptors in the cell nucleus, modulating gene transcription to increase metabolic rate, oxygen consumption, and protein, carbohydrate, and lipid metabolism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EUTHROID-3 and EUTHROID-2 depend on the specific clinical indication. These are both Thyroid Hormone Replacement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EUTHROID-3 is: Levothyroxine/liothyronine combination (EUTHROID-3): 1 tablet (50 mcg levothyroxine, 15 mcg liothyronine) orally once daily, adjusted based on TSH levels.. The standard adult dose of EUTHROID-2 is: Oral, 1 tablet once daily. Each tablet contains levothyroxine 112 mcg and liothyronine 28.8 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EUTHROID-3 and EUTHROID-2 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EUTHROID-3 is classified as Category C. Liothyronine (T3) and levothyroxine (T4) are endogenous thyroid hormones. Inadequate maternal thyroid hormone levels are teratogenic. At therapeutic doses, no known teratogenic ris. EUTHROID-2 is classified as Category C. EUTHROID-2 (levothyroxine 100 mcg + liothyronine 20 mcg) is a combination thyroid hormone replacement. Hypothyroidism itself increases risk of miscarriage and fetal neurodevelopmen. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.